Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Public Health. 2005 May;95(5):800-7.

Evaluating the safety of new vaccines: summary of a workshop.

Author information

1
Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA. sellenbe@cceb.upenn.edu <sellenbe@cceb.upenn.edu>

Abstract

Public concerns about the safety of vaccines arise on a regular basis. In November 2000, a workshop titled "Evaluation of New Vaccines: How Much Safety Data?" was convened by US Public Health Service agencies, including the Food and Drug Administration, the National Institutes of Health, the Centers for Disease Control and Prevention, and the Health Resources and Services Administration, to discuss appropriate methods for evaluating the safety of new vaccines. Workshop presentations addressed the current standards and approaches for new vaccine evaluation and postlicensure surveillance, as well as public views about vaccine safety and alternative approaches that could be considered. The advantages and disadvantages of conducting large controlled trials before licensure or widespread use of a new vaccine were discussed. We summarize these presentations and discussions.

PMID:
15855455
PMCID:
PMC1449258
DOI:
10.2105/AJPH.2004.039438
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center